Abstract:AIM: To determine the effects and possible signaling pathway of imidaprilat, an active type of angiotensin converting enzyme inhibitor (ACEI), on matrix metalloproteinases (MMPs) and type 2 tissue inhibitor of matrix metalloproteinase (TIMP-2) in human cardiac fibroblasts in the presence of interleukin-1β (IL-1β). METHODS: The primary human cardiac fibroblasts were purchased at passage 2 from Cell Systems. In the experiment, RT-PCR was used for analysis of transcription of MMPs and TIMP-2. Determination of proteolytic activity was performed with zymography. Assessment of nitric oxide (NO) production in the culture medium was performed by Griess reagent. RESULTS: IL-1β significantly increased MMP-2 activity, transcription and NO production in the supernatant of culture medium. These effects of IL-1β were inhibited by imidaprilat or NO synthase inhibitor N(superscript G)-methyl L-arginine. Sodium nitroprusside, an exogenous NO donor, prevented significantly the effects of imidaprilat on MMP-2 inhibition. Imidaprilat alone didn't affect MMP-2 activity and expression. Neither IL-1β nor imidaprilat had effect on TIMP-2 transcription in cardiac fibroblasts. CONCLUSION: Imidaprilat inhibits MMP-2 activity and expression in human cardiac fibroblasts induced by IL-1β via NO-dependent pathway. These data suggest that the beneficial effect of ACEI against left cardiac remodeling and heart failure may be due at least in part to regulating MMPs activity and expression by modulation of NO pathway.

Effects of Imidaprilat on Matrix Metalloproteinase - 2 and TIMP - 2 in Human Cardiac Fibroblasts